Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a malignant tumor with a fairly poor prognosis (5-year survival of less than 50%). Using sorafenib, the only food and drug administration (FDA)-approved drug, HCC cannot be effectively treated; it can only be controlled at most for a couple of months. There is a gre...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2020-12-01
|
| Series: | Liver Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2542568420300593 |